New York State Common Retirement Fund Reduces Position in Charles River Laboratories International, Inc. (NYSE:CRL)

New York State Common Retirement Fund reduced its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 4.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 131,078 shares of the medical research company's stock after selling 5,565 shares during the quarter. New York State Common Retirement Fund owned about 0.26% of Charles River Laboratories International worth $30,987,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. VisionPoint Advisory Group LLC raised its position in shares of Charles River Laboratories International by 105.7% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company's stock valued at $28,000 after buying an additional 74 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at $37,000. Operose Advisors LLC purchased a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at $42,000. Venturi Wealth Management LLC raised its position in shares of Charles River Laboratories International by 74.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company's stock valued at $51,000 after buying an additional 112 shares in the last quarter. Finally, Provence Wealth Management Group purchased a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at $57,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Charles River Laboratories International

In other news, EVP Victoria L. Creamer sold 5,000 shares of the firm's stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the completion of the sale, the executive vice president now directly owns 13,550 shares of the company's stock, valued at approximately $3,437,635. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Victoria L. Creamer sold 5,000 shares of the firm's stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the completion of the sale, the executive vice president now directly owns 13,550 shares of the company's stock, valued at approximately $3,437,635. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Shannon M. Parisotto sold 5,882 shares of the firm's stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares of the company's stock, valued at $626,155.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,932 shares of company stock valued at $3,693,663. Company insiders own 1.30% of the company's stock.

Analyst Ratings Changes

Several research firms have recently weighed in on CRL. UBS Group raised their price objective on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a "buy" rating in a research report on Thursday, February 15th. TheStreet raised shares of Charles River Laboratories International from a "c+" rating to a "b-" rating in a report on Friday, March 1st. JPMorgan Chase & Co. increased their target price on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the company an "overweight" rating in a report on Thursday, February 15th. Argus increased their target price on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the company a "buy" rating in a report on Monday, March 18th. Finally, Citigroup increased their target price on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a "neutral" rating in a report on Thursday, February 15th. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $253.23.

Charles River Laboratories International Trading Up 0.5 %

Charles River Laboratories International stock traded up $1.22 during trading hours on Friday, reaching $229.03. The stock had a trading volume of 322,036 shares, compared to its average volume of 551,216. The stock has a market cap of $11.80 billion, a PE ratio of 24.87, a PEG ratio of 1.88 and a beta of 1.40. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16. The company has a fifty day simple moving average of $253.48 and a 200-day simple moving average of $222.64.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. During the same quarter last year, the firm earned $2.98 EPS. The company's revenue was down 7.9% on a year-over-year basis. Analysts forecast that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).